Psilocybin for Major Depressive Disorder (MDD)

PHASE3RecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

March 13, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

December 30, 2026

Conditions
Depressive Disorder, Major
Interventions
DRUG

Psilocybin 25 mg

The Psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of Psilocybin.

DRUG

Inactive Placebo

The inactive placebo is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of Microcrystalline Cellulose (MCC). The MCC is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use.

DRUG

Psilocybin 5 mg

The Psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active comparator is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 5 mg of Psilocybin.

BEHAVIORAL

Psychosocial Support

Psychosocial Support, including psychoeducation, begins after the Double-blind Period and continues throughout the 1-year Follow-up Period in order to enhance participant safety and maximize retention for the entire trial duration.

Trial Locations (30)

10016

RECRUITING

NYU Clinical & Translational Science Institute, New York

10468

RECRUITING

Bronx Veterans Research Foundation at the James J. Peters VAMC, The Bronx

18507

WITHDRAWN

Scranton Medical Institute, LLC, Moosic

20850

ACTIVE_NOT_RECRUITING

Sunstone Medical PC, Rockville

21224

RECRUITING

Johns Hopkins School of Medicine, Center for Psychedelic and Consciousness Research, Baltimore

30030

RECRUITING

CenExel iResearch, LLC, Decatur

30329

RECRUITING

Emory University, Atlanta

32256

RECRUITING

Clinical Neuroscience Solutions Inc., Jacksonville

32801

RECRUITING

Clinical Neuroscience Solutions, Inc., Orlando

33319

RECRUITING

Innovative Clinical Research, Inc., Lauderhill

35209

RECRUITING

University of Alabama Clinical Research Unit, Birmingham

60640

RECRUITING

Great Lakes Clinical Trials, Chicago

63110

RECRUITING

Washington University School of Medicine, St Louis

68105

RECRUITING

VA Nebraska Western Iowa Health Care System, Omaha

72211

RECRUITING

Preferred Research Partners, Inc., Little Rock

72703

TERMINATED

Preferred Research Partners-NWA, LLC, Fayetteville

75093

RECRUITING

AIM Trials, LLC, Plano

78229

RECRUITING

Clinical Trials of Texas, LLC, San Antonio

80209

RECRUITING

Mountain View Clinical Research, Denver

84020

ACTIVE_NOT_RECRUITING

Cedar Clinical Research, Draper

84107

RECRUITING

Cedar Clinical Research, Inc., Murray

87106

RECRUITING

University of New Mexico (UNM) Interdisciplinary Substance Use and Brain Injury (ISUBI) Center, Albuquerque

90073

RECRUITING

West LA VA Medical Center - Mental Health Department, Los Angeles

90404

TERMINATED

Pacific Neuroscience Institute (PNI) at Saint John's Physician Partners, Santa Monica

RECRUITING

Psychedelic Science Institute, Santa Monica

92037

RECRUITING

Kadima Neuropsychiatry Institute, La Jolla

98004

RECRUITING

Seattle Neuropsychiatric Treatment Center, Bellevue

98661

RECRUITING

VA Portland Health Care System, Vancouver

06519

RECRUITING

Connecticut Mental Health Center, Yale University, New Haven

08540

RECRUITING

Global Medical Institutes, LLC; Princeton Medical Institute, Princeton

All Listed Sponsors
lead

Usona Institute

OTHER